John Oyler, BeiGene CEO (Endpoints News, PharmCube)
February 26, 2024 10:21 AM ESTUpdated March 2, 01:45 AM
Startups
Deals
Cell/Gene Tx

BeiGene ends pact with Shore­line, its 'en­try in­to cell ther­a­py'

Kyle LaHucik

Senior Reporter

BeiGene said its four-tar­get nat­ur­al killer cell ther­a­py col­lab­o­ra­tion with Shore­line Bio­sciences is over. And by reneg­ing on Shore­line’s iP­SC-NK cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times